Elite Health Systems Burns Cash Pre-Revenue, Secures MA Approvals

TL;DR

**EHSI is a pre-revenue gamble, burning cash fast, but their Medicare Advantage approvals offer a glimmer of hope for 2026 revenue.**

AI Summary

Elite Health Systems Inc. (EHSI) reported no revenue for the nine months ended September 30, 2025, and 2024, continuing its pre-revenue phase. The company incurred a net loss of $2,026,000 for the nine months ended September 30, 2025, a significant increase from the $1,034,000 net loss in the same period of 2024. Selling, general, and administrative expenses more than doubled to $2,036,000 for the nine months ended September 30, 2025, up from $1,299,000 in 2024, primarily due to increased operational setup costs for its new Medicare Advantage plan. EHSI's total assets grew to $5,311,000 at September 30, 2025, from $4,321,000 at December 31, 2024, driven by $992,000 in capitalized software under development. The company successfully raised $5,825,000 through a private sale of 11,650,000 common shares completed in January 2025 and an additional $1,890,000 as of September 30, 2025, from a second offering. EHSI received conditional state and federal approval for its Medicare Advantage plan in California in May and June 2025, respectively, and began marketing in October 2025, with significant revenue expected to commence in January 2026.

Why It Matters

EHSI's transition from radiation treatment centers to Medicare Advantage plans marks a pivotal, high-risk strategic shift. For investors, the lack of revenue and increasing losses, alongside reliance on equity financing, signals significant speculative risk. Employees and future customers in California and Nevada could benefit if EHSI successfully establishes its managed care network and attracts sufficient subscribers, challenging established players like Kaiser Permanente or UnitedHealthcare. However, failure to gain critical mass or manage expenses could lead to further dilution or operational distress, impacting market confidence in new entrants to the highly regulated healthcare insurance sector.

Risk Assessment

Risk Level: high — The company reported a net loss of $2,026,000 for the nine months ended September 30, 2025, and has an accumulated deficit of $6,471,000. These factors, combined with no current revenue and reliance on future capital raises, raise substantial doubt about its ability to continue as a going concern, as explicitly stated in the filing.

Analyst Insight

Investors should exercise extreme caution and consider EHSI a highly speculative investment. Monitor the company's progress in member enrollment and revenue generation starting January 2026, and assess its ability to secure additional capital beyond the $3,000,000 raised to date in the second offering.

Financial Highlights

debt To Equity

0.06

revenue

$0

operating Margin

N/A

total Assets

$5,311,000

total Debt

$291,000

net Income

-$2,026,000

eps

-$0.09

gross Margin

N/A

cash Position

$3,970,000

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $2,026,000 — Net Loss (For the nine months ended September 30, 2025, a significant increase from $1,034,000 in 2024.)
• $0 — Revenue (For the nine months ended September 30, 2025 and 2024, indicating pre-revenue status.)
• $6,471,000 — Accumulated Deficit (As of September 30, 2025, up from $4,445,000 at December 31, 2024.)
• $5,825,000 — Capital Raised (Through private sale of 11,650,000 common shares completed January 2025.)
• $1,890,000 — Capital Raised (From second offering as of September 30, 2025, with a target of $3,000,000 to $5,000,000.)
• 21,939,924 — Common Shares Outstanding (As of October 31, 2025, reflecting significant dilution from prior periods.)
• $992,000 — Capitalized Software Under Development (As of September 30, 2025, up from $0 at December 31, 2024, reflecting investment in new business.)
• January 2026 — Expected Revenue Commencement (From Medicare Advantage Plan operations.)

Key Players & Entities

• Elite Health Systems Inc. (company) — Registrant and parent company
• Elite Health Plan, Inc. (company) — Wholly-owned subsidiary awarded Knox-Keene license
• Centers for Medicare and Medicaid Services (regulator) — Approved EHP's Medicare Advantage contract
• Physician Support Systems, Inc. (company) — Acquired by EHSI on November 1, 2025
• California (location) — Primary market for Medicare Advantage plans
• Nevada (location) — Target market for future Medicare Advantage plans
• U.S. NeuroSurgical Holdings, Inc. (company) — Former name of Elite Health Systems Inc.
• Knox-Keene license (regulatory) — License to offer managed health care plans in California

FAQ

Risk Factors

• Sustained Net Losses and Accumulated Deficit [high — financial]: EHSI reported a net loss of $2,026,000 for the nine months ended September 30, 2025, a significant increase from $1,034,000 in the prior year period. The accumulated deficit grew to $6,471,000 as of September 30, 2025, from $4,445,000 at December 31, 2024. This indicates ongoing operational costs exceeding revenue, requiring continuous funding.
• Dependence on New Medicare Advantage Plan Launch [high — operational]: The company's future revenue is entirely dependent on the successful launch and performance of its new Medicare Advantage plan. While conditional state and federal approval was received in May and June 2025, and marketing began in October 2025, significant revenue is not expected until January 2026. Any delays or underperformance in this single venture poses a substantial risk.
• Significant Increase in SG&A Expenses [medium — financial]: Selling, general, and administrative expenses more than doubled to $2,036,000 for the nine months ended September 30, 2025, up from $1,299,000 in the same period of 2024. This increase is primarily attributed to operational setup costs for the new Medicare Advantage plan, signaling rising expenditures ahead of revenue generation.
• Dilution from Capital Raises [medium — financial]: EHSI raised $5,825,000 in January 2025 and an additional $1,890,000 as of September 30, 2025. This was accompanied by a significant increase in common shares outstanding to 21,939,924 as of October 31, 2025, from 19,984,924 at December 31, 2024. This dilution impacts existing shareholders' equity per share.
• Medicare Advantage Program Compliance [high — regulatory]: Operating a Medicare Advantage plan requires strict adherence to complex federal and state regulations. Non-compliance can lead to significant penalties, fines, or loss of operating licenses, directly impacting the company's ability to generate revenue and operate.

Industry Context

The health insurance industry, particularly the Medicare Advantage segment, is highly regulated and competitive. Companies must navigate complex compliance requirements and demonstrate value to beneficiaries and the government. Growth in Medicare Advantage is driven by an aging population and the comprehensive benefits offered compared to traditional Medicare. Success hinges on efficient operations, strong provider networks, and effective marketing.

Regulatory Implications

EHSI's primary revenue stream is contingent on its Medicare Advantage plan. Obtaining and maintaining state and federal approvals is paramount. Any changes in Medicare regulations, reimbursement rates, or compliance failures could severely impact the company's financial viability and operational capacity.

What Investors Should Do

1. Monitor the Medicare Advantage plan launch closely for any signs of delay or operational issues, as this is the sole revenue driver.
2. Analyze the burn rate and cash runway, given the increasing net losses and SG&A expenses, to assess the need for future capital raises.
3. Evaluate the impact of share dilution on existing equity value and future earnings per share.
4. Assess the company's ability to manage regulatory compliance within the Medicare Advantage framework.
5. Compare EHSI's progress and operational costs against industry benchmarks once revenue generation begins.

Key Dates

• 2025-01-01: Private sale of 11,650,000 common shares completed — Provided $5,825,000 in capital to fund operations and development.
• 2025-05-01: Conditional state approval for Medicare Advantage plan in California received — Key regulatory milestone enabling the launch of the company's primary revenue-generating service.
• 2025-06-01: Conditional federal approval for Medicare Advantage plan in California received — Further critical regulatory approval, paving the way for operational readiness.
• 2025-10-01: Marketing for Medicare Advantage plan began — Initiation of customer outreach and sales efforts in anticipation of revenue commencement.
• 2025-09-30: Second offering raised $1,890,000 — Additional capital infusion to support ongoing operations and growth initiatives.
• 2026-01-01: Expected revenue commencement from Medicare Advantage Plan operations — Marks the transition from a pre-revenue to a revenue-generating company, critical for future viability.

Glossary

Accumulated Deficit

The cumulative net losses of a company that have not been offset by net income. It represents the total losses incurred since the company's inception. (Indicates the company has consistently operated at a loss, with the deficit increasing to $6,471,000 as of September 30, 2025.)

Capitalized Software Under Development

Costs incurred in developing software that are capitalized on the balance sheet rather than expensed immediately. These costs are expected to provide future economic benefits. (Represents a significant investment of $992,000 in developing the technology infrastructure for the new Medicare Advantage plan.)

Pre-revenue phase

A stage in a company's lifecycle where it has not yet generated any sales or revenue from its primary business operations. (EHSI is currently in this phase, with no revenue reported for the nine months ended September 30, 2025 and 2024.)

Common Shares Outstanding

The total number of shares of a company's common stock that are held by all its shareholders, including restricted shares owned by insiders and the public. (The number of shares outstanding increased significantly to 21,939,924 by October 31, 2025, due to recent capital raises, indicating potential dilution for existing shareholders.)

Stock to be issued

Represents shares that have been committed to be sold or issued but have not yet been formally transferred to the buyer or recorded as fully issued and outstanding. (Shows $1,890,000 related to a second offering as of September 30, 2025, which is part of the capital raised.)

Year-Over-Year Comparison

Compared to the prior year period, EHSI has seen a significant increase in its net loss, nearly doubling to $2,026,000 for the nine months ended September 30, 2025, from $1,034,000 in 2024. This is driven by a substantial rise in SG&A expenses, which more than doubled to $2,036,000, primarily due to setup costs for its new Medicare Advantage plan. Total assets have grown to $5,311,000, largely from capitalized software development, while the accumulated deficit has also widened considerably. No new significant risks have emerged, but existing ones related to operational execution and financial sustainability remain prominent.

Key Financial Figures

• $0.01 — hares of the registrant's common stock, $0.01 par value, outstanding as of October 31

Filing Documents

• ehsi20250930_10q.htm (10-Q) — 629KB
• ex_885399.htm (EX-31.1) — 13KB
• ex_885400.htm (EX-31.2) — 12KB
• ex_885401.htm (EX-32.1) — 5KB
• 0001437749-25-034794.txt ( ) — 3490KB
• ehsi-20250930.xsd (EX-101.SCH) — 30KB
• ehsi-20250930_def.xml (EX-101.DEF) — 244KB
• ehsi-20250930_lab.xml (EX-101.LAB) — 180KB
• ehsi-20250930_pre.xml (EX-101.PRE) — 256KB
• ehsi-20250930_cal.xml (EX-101.CAL) — 28KB
• ehsi20250930_10q_htm.xml (XML) — 391KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 3

Financial Statements

Item 1. Financial Statements 3

Management Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management Discussion and Analysis of Financial Condition and Results of Operations. 16

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk. 20

Controls and Procedures

Item 4. Controls and Procedures 21

– OTHER INFORMATION

PART II – OTHER INFORMATION 22

Legal Proceedings

Item 1. Legal Proceedings 22 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities Unregistered Sales of Equity Securities and Use of Proceeds 23

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 23

Submission of Matters to a Vote of Security Holders

Item 4. Submission of Matters to a Vote of Security Holders 23

Other Information

Item 5. Other Information 23

Exhibits

Item 6. Exhibits 23

SIGNATURES

SIGNATURES 24 2 Table of Contents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements ELITE HEALTH SYSTEMS INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS September 30, December 31, 2025 2024 (Unaudited) (Audited) ASSETS Current assets: Cash and cash equivalents $ 3,970,000 $ 4,034,000 Other current assets 302,000 28,000 Due from related parties 1,000 12,000 Stock subscriptions receivable - 175,000 Total current assets 4,273,000 4,249,000 Property and equipment: Capitalized software under development 992,000 - Operating lease right-of-use asset 46,000 72,000 Total property and equipment 1,038,000 72,000 TOTAL ASSETS $ 5,311,000 $ 4,321,000 LIABILITIES Current liabilities: Operating lease right-of-use liability - current portion $ 37,000 $ 34,000 Accounts payable and accrued expenses 233,000 60,000 Total current liabilities 270,000 94,000 Operating lease right-of-use liability - net of current portion 10,000 38,000 Guarantee liability 11,000 11,000 Total liabilities 291,000 143,000 EQUITY Common stock - par value $ .01 ; 25,000,000 shares authorized; 21,939,924 . and 19,984,924 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively. 220,000 200,000 Stock to be issued 1,890,000 238,000 Additional paid-in capital 9,381,000 8,185,000 Accumulated deficit ( 6,471,000 ) ( 4,445,000 ) Total stockholders' equity 5,020,000 4,178,000 TOTAL LIABILITIES AND EQUITY $ 5,311,000 $ 4,321,000 See accompanying notes to the consolidated financial statements 3 Table of Contents ELITE HEALTH SYSTEMS INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 Revenue $ - $ - $ - $ - Costs and expenses: Selling, general and administrative 1,165,000 387,000 2,036,000 1,299,000 Total expense 1,165,000 387,000 2,03

View Full Filing

View this 10-Q filing on SEC EDGAR